Results 131 to 140 of about 261,105 (346)
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors [PDF]
Everett E. Vokes +5 more
openalex +1 more source
History of Paclitaxel and Oral Paclitaxel – Clinical Data and Future [PDF]
Ganesh H Divekar +2 more
openaire +2 more sources
Hesperidin nanoparticles (HE NPs) effectively combat obesity and sleep‐disordered breathing in mice by enhancing leptin sensitivity. Through suppression of hypothalamic endoplasmic reticulum stress and restoration of leptin signaling, HE NPs promote weight loss and improve breathing during sleep.
Yixuan Wang +11 more
wiley +1 more source
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group [PDF]
Jan P. van Meerbeeck +11 more
openalex +1 more source
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
D. V. Von Hoff +22 more
semanticscholar +1 more source
APOL2 Stabilizes Ku80 to Confer NHEJ‐Mediated Radioresistance in Gastric Cancer
Radiotherapy resistance in gastric cancer (GC) is often mediated by enhanced DNA repair. APOL2 is found to promote NHEJ by stabilizing Ku80, conferring radioresistance. High APOL2 correlates with poor prognosis. Formononetin disrupts APOL2‐Ku80, restoring radiosensitivity, suggesting a novel therapeutic strategy.
Dan Zu +23 more
wiley +1 more source
Background Paclitaxel, a tubulin-binding agent, is a Food and Drug Administration-approved first-line drug for the treatment of non-small cell lung cancer (NSCLC), for both squamous and non-squamous cell lung carcinoma, with paclitaxel/carboplatin ...
Yanyan Lu +3 more
doaj +1 more source
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium [PDF]
Christopher J. Sweeney +7 more
openalex +1 more source
This study shows that diabetes damages sensory nerve fibers, especially CGRP‐positive ones, in the periodontium and disrupts autophagy in trigeminal ganglion neurons, affecting bone homeostasis by inhibiting type H vessel formation. To address this, CGRP@PVA/tsPBA hydrogels are developed to release CGRP in response to ROS, which binds to endothelial ...
Chaoning Zhan +7 more
wiley +1 more source
M, Díaz, M A, Campanero
openaire +2 more sources

